Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ALJ Initial Decisions:
Administrative Law Judges
http://www.sec.gov/alj/aljdec/2014/id588bpm.pdf
BZEC SEC Suspension:
http://www.sec.gov/litigation/suspensions/2014/34-71683.pdf
Order:
http://www.sec.gov/litigation/suspensions/2014/34-71683-o.pdf
Admin Proceeding:
http://www.sec.gov/litigation/admin/2014/34-71682.pdf
BZEC .002 extreme 10day avg volume change going 535k verses http://www.profitspi.com/stock/view.aspx?v=price-and-chart&p=3871&i=BZEC&pv=recent-symbols&pp=BZEC#&&vs=635083729505858446
Wow, whats going on here?
BZEC - Bid building here and .025 Now - Holding a nice chunk for next PR.
Angry life.....I have owned a little, for several years now, been through the crushing reverse split, name changes, etc.....When will the breast cancer detection thing ever "make it"? Or is it complete "quackery"?........A dud of a penny stock........
There is life on this board............
Great news. When will it lead the stock to higher PPS? And now another name change. Go Mackay?
BZEC (.021) NEWS - Biofield Corporation's 51% Owned Subsidiary Agrees to Deal Appointing McKinley Infocapital as Korean Exclusive Distributor of Breast Cancer Diagnostic System; Contract has Potential Value of up to $15.3 Million
Apr 8, 2011 9:45:00 AM
Close Ad
Email story | Discuss on ZenoBank | View more ads
NEW YORK, April 8, 2011 /PRNewswire/ -- Biofield Corp. (OTC Pink: BZEC) announced today that its 51% owned subsidiary, Sky Unicorn Holdings Ltd., has engaged McKinley Infocapital as its exclusive distributor in Korea for its flagship product, the Biofield Breast Diagnostic System (BDS). McKinley Infocapital, an international business consulting and investment management firm, has formed MacKay Life Sciences Korea to market and promote the BDS in Korea.
The agreement provides for an initial purchase order in the amount of $660,000, and it further provides for an initial deposit of $330,000 on that first order. The terms also include a total minimum order of $900,000 for the first year of the engagement. The duration of the agreement features a term of four years from the effective date. If the annual minimum purchase volume requirements are met, the total potential value of the agreement is $15.3 million over that timeframe, although, to date, no payments have been made or received under the agreement. The conditions and terms of the distribution agreement are subject, in all respects, to the BDS obtaining the approval of the Korea FDA for import and sale of the product in Korea.
At the signing ceremony for the exclusive distribution agreement, McKinley Infocapital President, Mr. Halen Bach, expressed, "McKinley Infocapital is very excited to have achieved this milestone and looks forward to expanding the penetration of the MacKay Life Science BDS in both Korea and other Asian Countries where it operates with a large network of corporate clients."
After patient trials were conducted earlier this year in Korea at the CHA Hospital and the Seoul National University Hospital, Biofield President David Hong was thrilled with the positive feedback that was received from the surgeons and physicians that participated in or observed the patient trials. Participating experts expressed that the BDS "is a significant break-through in enabling clinicians to recognize problems within the mammary glands at such an early stage and with such a high accuracy rate." Hong commented, "Because the technology is able to identify cancer at an early stage, it gives patients the opportunity for early detection of breast cancer, which is the key to saving lives. Further, this will be an excellent opportunity to work closely with McKinley Infocapital in expanding our R&D capabilities in order to broaden the application of our patented technology to assist in the fight against other forms of cancer."
The distribution agreement also includes an option for McKinley Infocapital to acquire the exclusive distribution rights for the following Asian and Southeast Asian countries: Japan, Thailand, Vietnam, Malaysia, Cambodia, Laos, and Myanmar. Each territory would require its own separate Exclusive Distributorship Agreement and associated licensing fees.
About Biofield Corp.
Biofield Corp., a medical technology company, engages in the development and provision of non-invasive diagnostic medical devices to assist in the detection breast cancer. If offers the Biofield Diagnostic System, a breast cancer diagnostic device, which employs single-use sensors designed to measure and analyze changes in cellular electrical charge distributions associated with the development of epithelial cancers, such as breast, ovarian, skin, prostate, and colon cancers. The company's device is intended for use with palpable breast lesions in women under 55 years of age. For more information, visit http://www.biofield.com.
About McKinley Infocapital
McKinley Infocapital is a leading international business consulting and investment management firm offering a wide range of professional services. McKinley Infocapital's longstanding association with leading law and accounting firms, as well as the investment community, enables McKinley Infocapital its professionals to deliver effective, highly integrated and effective management solutions. For more information, visit http://www.themckinley.com/.
SAFE HARBOR STATEMENT: Certain statements made in this press release should be considered forward-looking and subject to various risks and uncertainties. Such forward-looking statements are based on management's belief, as well as assumptions made by, and information currently available to, management pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can generally be identified as such because the context of the statement will include words such as "believes", "anticipates", "appears", "expects", "should", "may", or words of similar import. Similarly, statements that describe the company's future plans, objectives, estimates or goals are also forward-looking statements. Such statements may address future events and conditions. Additional factors which should be considered are set forth in the company's Annual Report on Form 10-KSB and Quarterly Report on Form 10-QSB. Copies of such documents can be obtained from EDGAR database Internet website maintained by the Securities and Exchange Commission at http://www.sec.gov/edgarhp.htm. The company undertakes no obligation to release publicly the results of any revisions to its forward-looking statements that may be made in this press release to reflect events or circumstances occurring after the date of this press release. Without limiting the generality of the foregoing, there cannot be any assurance that the Company will receive the initial deposit, initial purchase order amount, minimum first year purchases or future minimum purchase amounts under the agreement discussed herein.
Contact: Michael Zarraga, +1-215-972-1717, mz@biofield.com
SOURCE Biofield Corporation
What a piece of crud stock. Ever since thier name change, and "quality" reverse split, this stock has just plain died. Anybody out there have any clue on whether there's still a pulse present?
I saw in Google finance 70 million or so was spent researching and redeveloping this product they wouldn't do that if they wont be re applying for FDA approval wont they hmm..? i see the trades start to pick up again for 2 straight days already. IMO this is gonna rocket again. But a name change? Whats cooking?
MacKay Life Sciences, Inc. (Formerly Biofield Corp.) to Re-Acquire Control of Its Master License; Signs Agreement to Acquire Majority Interest In MacKay Innotech LTD, Present Holder of the Master License
http://investing.businessweek.com/research/stocks/news/article.asp?docKey=600-200906301600BIZWIRE_USPR_____BW6268-7IB9LFM95O04THURLT2818TAMQ¶ms=timestamp||06/30/2009%204:00%20PM%20ET||headline||MacKay%20Life%20Sciences%2C%20Inc.%20%28Formerly%20Biofield%20Corp.%29%20to%20Re-Acquire%20Control%20of%20Its%20Master%20License%3B%20Signs%20Agreement%20to%20Acquire%20Majority%20Interest%20In%20MacKay%20Innotech%20LTD%2C%20Present%20Holder%20of%20the%20Master%20License||docSource||Business%20Wire||provider||ACQUIREMEDIA||realtedsyms||%7CUS%3BBZEC&ric=BZEC.OB
July 02, 2009 9:25 PM ET
PHILADELPHIA & HONG KONG--(BUSINESS WIRE)-- MacKay Life Sciences, Inc. ("MLS") (formerly Biofield Corp. (OTCBB:BZEC), today announced that it has signed a binding Memorandum Of Agreement ("MOU") with the master licensee to complete the long awaited reacquisition of the master license agreement (the "MLA") that the company had previously granted to the MacKay Group Limited ("MKG"). MKG has since transferred the master license to MacKay Innotech LTD, ("MHK"), a Hong Kong company. Under the MLA, MKG (now MHK as a result of the assignment) assumed from Biofield the sole responsibility and expense to market, manufacture, further technically and clinically develop, and otherwise commercialize the technology.
Under the terms of the MOU, MLS will initially acquire 51% of MHK in return for cash and stock. The terms also call for a royalty of 10% to MKG on licensing deals previously signed by MKG during its (and MHK's) prior tenure as the holder of the MLA. MLS also has the right to acquire up to 100% of the private MHK. The company will be filing an 8K to further specify the terms of the proposed transaction. When closed, this will allow the company, to recognize 100% of the revenues of MHK as its own since MHK will be treated as a wholly owned subsidiary. The transaction will close as soon as a valuation of MHK is conducted and mutually agreed upon by the parties. The agreed upon valuation will provide the dollar value of the amount of shares that will be issued to MHK for the acquisition. The Cash component will be $5 million, in the form of a Convertible Note. Closing is to take place within 30 days or less. Closing may be mutually extended by the parties an additional 14 days.
One contingency for Closing of the MOU is that MKG requires MLS to reach an acceptable agreement with its remaining noteholders, to convert their remaining debt, to shares of restricted common stock which will take place in a contemporaneous transaction with the MOU. The Company in 2005, raised $1.3 million in debt financing. Several months ago, the Company's largest non-affiliated Institutional Investor, the Capital Growth Equity Fund I, LLC (the "Equity Fund") converted $422,000 of debt and accrued interest and invested another $110,000 of equity as well and partially reduced the debt.
About MacKay Life Sciences, Inc.
MacKay Life Sciences, Inc., is a medical technology company which develops and acquires noninvasive diagnostic medical devices to assist in detecting and preventing cancer and other illnesses. The Company has reoriented and expanded its energies to focus on offering non-invasive and cost effective technologies, on an easily accessible basis, to the world's largest population centers. For more information go to: www.mackaylifesciences.com
About MKG
MKG is a private corporation that pursues diverse and significant opportunities around the globe. It has a portfolio of investments in a variety of companies, ventures, and projects. MKG has gained the respect of government and industry leaders around the world and has been instrumental in establishing a world wide distribution channel for the Biofield portfolio of products. For more information go to: www.themackaygroup.net
SAFE HARBOR STATEMENT: This news release contains "forward-looking statements" made pursuant to the safe harbor provisions of the 1995 Private Securities Litigation Reform Act. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." Such statements are subject to risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that our products may not achieve customer acceptance or perform as intended, that we may be unable to obtain necessary financing to continue operations and development, and other risks. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.
Source: MacKay Life Sciences, Inc.
they've already posted their press releases...check it out...
a lot of things now happening in BZEC mackay life sciences or formerly known as biofield corp.
watch out!
Biofield Announces Name Change and Exclusive Distributor For Mexico, Central and Latin America; Distribution Terms Include $1 Million Licensing Fee and 10% Royalty of Gross Revenue
http://www.earthtimes.org/articles/show/biofield-announces-name-change-and,874281.shtml
PHILADELPHIA & HONG KONG - (Business Wire) Biofield Corp. (OTCBB:BZEC), today announced that it has shipped the initial order of its proprietary Biofield Diagnostic System for the early detection of breast cancer units (the “BDS”), to an exclusive distributor representing the Mexican, Central and Latin American markets. The distributor, MacKay Health Systems, (“MHS”), a company primarily made up of nationals from the licensed territories, acquired the rights to Mexico and various Central & Latin American countries via an exclusive distribution agreement it entered into with MacKay Innotech LTD, (“MHK”), a Hong Kong company. MKH holds a worldwide master license from Biofield to manufacture and distribute the BDS units.
Under the terms of distribution agreement, MHS will pay MHK a non-refundable licensing fee of $1 million dollars and 10% Royalty of Gross Revenues. Terms require the distributor to purchase a minimum number of units per quarter, per country. The specific countries are: Aruba, Belize, Costa Rica, Dominican Republic, El Salvador, Guadeloupe, Guatemala, Haiti, Honduras, Martinique, Mexico, Netherland Antilles, Nicaragua, Puerto Rico. Saint Martin and Saint Pierre & Miquelon. The company has, this week, shipped the initial order, as per the terms of the agreement. Regular recurring shipments are expected to follow.
The company, which recently completed its transformation from a medical technology company which solely developed and distributed its own proprietary technology (the BDS unit) to one that also has and seeks to acquire other, primarily, noninvasive diagnostic medical devices to assist in detecting and preventing cancer and other illnesses. After acquisition, the company then distributes these non-invasive and cost effective technologies and devices, by first targeting the world’s largest population centers.
Biofield has acquired 10% of ValiRx PLC listed on the UK’s AIM stock exchange together with the right for the exclusive worldwide distribution rights outside of Belgium, for ValiRx plc’s Human Papilloma Virus (HPV) diagnostic test for cervical cancer as well as for ValiBio Hypergenomics™.
The company also announced its intention to change its name to “MacKay Life Sciences, Inc.” The name change is also meant to precede closing of the previously announced intention of MHK to vend back into the company, the master license MHK holds, in addition to the rights and agreements that MHK has amassed during its term as the master licensee, which should result in greater revenues being realized by the public company.
About Biofield Corp.
Biofield is a medical technology company which develops and acquires noninvasive diagnostic medical devices to assist in detecting and preventing cancer and other illnesses. The Company has reoriented and expanded its energies to focus on offering non-invasive and cost effective technologies, on an easily accessible basis, to the world’s largest population centers. For more information go to: www.biofield.com.
About MHK
MHK is a private corporation that pursues diverse and significant opportunities around the globe. It has a portfolio of investments in a variety of companies, ventures, and projects. MHK has gained the respect of government and industry leaders around the world and has been instrumental in establishing a world wide distribution channel for the Biofield portfolio of products. For more information go to: www.themackaygroup.net
About The CorpFin Group, LLC:
The CorpFin Group is a leading South Florida based Advisory Firm whose mission is to combine Management's vision, with the experience of our Advisor's to maximize equity value. Our Focus on Value Creation enables us to bring an original, independent view and unique expertise to the opportunities and challenges that business leaders face. Our services include: Strategic Planning, Leadership & Organization, Transitional Management, Accessing & Controlling Capital, Risk Avoidance, Transitional & Alternative Public Offerings, Mergers, Acquisitions & Alliances. Coordination of Public Company Reporting and SOX Compliance, Investor Relations, Business Valuations & Fairness Opinions & Going Private Transactions. For more information go to: www.CorpFingrp.com
SAFE HARBOR STATEMENT: This news release contains "forward-looking statements" made pursuant to the safe harbor provisions of the 1995 Private Securities Litigation Reform Act. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." Such statements are subject to risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that our products may not achieve customer acceptance or perform as intended, that we may be unable to obtain necessary financing to continue operations and development, and other risks. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.
The CorpFin Group
Michael S. Jacobs, 561-962-4159
Michael@corpfingrp.com
www.CorpFingrp.com
President Michael Yom in an email stated that the company hopefully soon will release a shareholder update about the future of the company. Im not concerned about when because most of us that are in SSTY know that james mackay is busy in china and europe getting SSTY/TPID all set up for contracts that they claim are already there but had to build up the infastructure to meet those contracts. I think this stock will take off soon because of Mr. Mackays contracts and funding in china, where these products from bzet are mainly marketed towards.
Health issues are big now-a-days, especially in relation to breast cancer ... this has some potential, I'll kee my eye on this one. When will we hear some more news?
Welcome everyone to the BZET board. DD this company if you havnt already. THis is the ground floor for an exciting beginning. We shall see if James Mackay can bring his connections and expertise to this company.
Followers
|
7
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
23
|
Created
|
04/27/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |